Dermaxmed

Dermaxmed is a clinical-stage biotechnology company focused on the development of innovative therapies for immune-mediated inflammatory skin diseases. The company's primary focus is on the development of highly selective Janus kinase (JAK) inhibitors designed to provide superior efficacy and safety profiles for dermatological conditions. Their lead candidate is being evaluated for its potential to treat chronic skin disorders such as atopic dermatitis and alopecia areata. By leveraging expertise in medicinal chemistry and dermatology, Dermaxmed aims to address significant unmet medical needs in the field of medical aesthetics and therapeutic dermatology. The company operates primarily in China, conducting clinical trials to advance its pipeline toward commercialization.